
    
      This study is designed as randomized, open-label, active-controlled and crossover assignment
      for evaluate and compare the safety and pharmacokinetics of NVP-1402 and NVP-1402R in healthy
      male subjects. The safety assessed through adverse events up to 17 days after administration.
      Additional variables (ECGs, laboratory test, vital signs, so on) will also be recorded and
      assessed.
    
  